Literature DB >> 7548510

Invasive pneumococcal disease in central Australia.

J Trotman1, B Hughes, L Mollison.   

Abstract

Invasive pneumococcal disease remains a major problem in certain groups of people. We undertook a hospital-based review of all cases of invasive pneumococcal disease in central Australia over a 2-year period. We observed 79 cases of invasive disease in 78 patients. The incidence of invasive pneumococcal disease was highest in Aborigines under 5 years of age (1,025 cases per 100,000 population per year). The relative risk for Aborigines compared with non-Aborigines was 31.6 (95% CI, 12.8-78.1). Pneumonia was the commonest disease observed (82% of patients). Eight patients died (10.1%), and all of these patients had identifiable risk factors for pneumococcal disease. Serotyping showed that all except two isolates were covered by the existing 23-valent pneumococcal vaccine. These data reveal that Aborigines in central Australia have the highest reported rate of invasive pneumococcal disease in the world. A vaccination program in central Australia should decrease admissions and deaths due to pneumococcal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548510     DOI: 10.1093/clinids/20.6.1553

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Gram-Positive Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in central Australia.

Authors:  M Gratten; P Torzillo; F Morey; J Dixon; J Erlich; J Hagger; J Henrichsen
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

Review 3.  Epidemiology of pneumococcal infections in the elderly.

Authors:  J C Butler; A Schuchat
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

Review 4.  What can children gain from pneumococcal conjugate vaccines?

Authors:  Heikki Peltola; Robert Booy; Heinz-Josef Schmitt
Journal:  Eur J Pediatr       Date:  2004-06-10       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.